Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Oct 30, 2022
Trial Information
Current as of April 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying patients with dry eyes caused by Primary Sjögren's syndrome, a long-lasting condition where the immune system mistakenly attacks the body's moisture-producing glands. The goal is to better understand how different forms of this condition affect dry eye symptoms and to find ways to help manage them. The study is currently recruiting participants aged between 65 to 74 years old, as well as those between 29 to 219 years old, regardless of gender.
To be eligible for the trial, participants must have been diagnosed with dry eye according to specific guidelines and meet the criteria for Primary Sjögren's syndrome. However, those with certain other health conditions, histories of eye surgery or trauma, contact lens use, or specific eye problems will not be able to join. Participants can expect to undergo various examinations and assessments related to their eye health. Additionally, this study aims to gather important data that could lead to better treatments for people suffering from dry eyes linked to this syndrome.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All enrolled DED participants met the criterion of TFOS DEWS II Definition and Classification Report and pSS-DED group also met 2016ACR/EULAR pSS diagnosis and classification consensus.
- Exclusion Criteria:
- • (1) patients were diagnosed as any rheumatic or systematic diseases that would probably affect tear function except for pSS and DED. (2) had a history of ocular trauma or surgery. (3) had a history of wearing contact lens. (4) had concomitant ocular lesions such as acute inflammation or infection, glaucoma or eyelid abnormalities. (5) cannot cooperate properly or finish related examinations.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, , China
Patients applied
Trial Officials
Liyuan Tao, PhD
Study Chair
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials